Double-blind, randomized, placebo-controlled, parallel-group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis

Trial Profile

Double-blind, randomized, placebo-controlled, parallel-group, multicenter/multinational, efficacy and safety study of desloratadine 5 mg in the treatment of subjects with allergic rhinitis who meet the criteria for persistent allergic rhinitis

Completed
Phase of Trial: Phase III

Latest Information Update: 17 Apr 2017

At a glance

  • Drugs Desloratadine (Primary)
  • Indications Perennial allergic rhinitis
  • Focus Therapeutic Use
  • Acronyms ACCEPT-2
  • Sponsors Merck Sharp & Dohme; Schering-Plough
  • Most Recent Events

    • 17 Mar 2009 Results reported at AAAAI 2009.
    • 06 May 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.
    • 20 Mar 2008 The expected completion date for this trial is now 1 Mar 2008, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top